PetMeds 2.0 1) Adjusted EBITDA and adjusted EBITDA per share are non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures. 12 Investment Highlights Expert well-known online pet pharmacy with over 2 million unique customers Strong market demand for pet medication in pet category resilient to economic headwinds Broader strategic plan – expansion of new customers, more products, unique and ...

Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from _____________ to _____________ Commission file number: 000-28827 ________________________ PETMED EXPRESS, INC. (Exact name of registrant as specified in its ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) Washington D.C. 20549 For the transition period from _____________ to _____________ Commission file number: 000-28827 ________________________ PETMED EXPRESS, INC. (Exact name of registrant as specified in its charter) ________________________ (State or other jurisdiction of incorporation or organization) FLORIDA 65-0680967 (I.R.S. Employer Identification No.) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 000-28827 ______________________ PETMED EXPRESS, INC. (Exact name of registrant as specified in its chart ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-28827 PETMED EXPRESS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Exact name of registrant as specified in its charter) (State or other jurisdiction of (IRS Employ ...

Financial Data and Key Metrics Changes - Fourth quarter sales were USD66 million, a decrease of 7.9% compared to USD71.7 million for the same period last year [30] - Net income for the fourth quarter was USD6.1 million, or USD0.30 diluted per share, down from USD6.8 million, or USD0.34 diluted earnings per share, reflecting an 11% decrease [36] - Adjusted EBITDA for the fourth quarter was USD9.5 million, or USD0.47 on a diluted basis, down 8.4% from USD10.4 million, or USD0.52 on a diluted basis, for the same quarter last year [37][38] Business Line Data and Key Metrics Changes - The AutoShip & Save subscription program accounted for approximately 37% of revenue in March, a 41% increase from the previous quarter [9][32] - New order sales decreased by 35% to USD4.9 million for the quarter, compared to USD7.4 million for the same quarter last year [33] - Reorder sales decreased by 4.8% to USD61.1 million for the quarter, compared to USD64.2 million for the same quarter last year [34] Market Data and Key Metrics Changes - The U.S. pet market is over USD100 billion in annual sales and is expected to reach USD120 billion by 2024, with the addressable pet medication market at approximately USD10 billion [11] - The company operates in a growing market with favorable trends towards digital retail, as 7 out of 10 U.S. households own pets [14][15] Company Strategy and Development Direction - The company is transitioning from a leading pet medication retailer to a market leader in expert pet healthcare, focusing on nutrition, medications, wellness, and care [43] - A strategic partnership with Vetster was announced to enhance telemedicine capabilities, marking a significant step in the company's pet health expert strategy [10][48] Management's Comments on Operating Environment and Future Outlook - Management noted that revenue declines have begun to moderate, with expectations for sales in flea and tick categories to rebound as temperatures rise [6] - The company is committed to becoming a higher-growth entity while maintaining a strong balance sheet with no debt and approximately USD111 million in cash [25][38] Other Important Information - The Board of Directors declared a quarterly dividend of USD0.30 per share, payable on May 27, 2022 [39] - The company has a strong customer base with over 2 million pet parents having purchased from them in the last two years, and an NPS score over 80 [26] Q&A Session Summary Question: What are the demand trends for flea and tick season? - Management acknowledged a slow start to the flea and tick season due to colder weather in March, but expressed confidence in a rebound as temperatures rise [54][56] Question: How should advertising spend be framed for fiscal 2023? - Advertising spend was down about USD800,000 or 20% from the previous year, with expectations to maintain similar spending levels but with improved efficiency [60] Question: What are the financial contributions expected from the telemedicine partnership? - Management did not provide specific guidance on the financial impact of the telemedicine partnership but expressed excitement about the potential growth opportunities it presents [58][59] Question: Should future transactions be expected to be of similar size to Vetster? - Management indicated that they are open to various types of partnerships and investments, including M&A, as they seek to fill gaps in their service offerings [70][71]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 000-28827 PETMED EXPRESS, INC. (Exact name of registrant as specified in its charter) Florida 65-0680 ...

PetMed Express, Inc. (NASDAQ:PETS) Q3 2021 Results Earnings Conference Call January 24, 2022 4:30 PM ET Company Participants Matt Hulett - Chief Executive Officer Bruce Rosenbloom - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Anthony Lebiedzinski - Sidoti & Company Corey Grady - Jefferies Ben Rose - Battle Road Research Operator Welcome to the PetMeds Conference Call to Review the Financial Results for the Third Fiscal Quarter ended on December 31, 2021. At the request ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 000-28827 ______________________ PETMED EXPRESS, INC. (Exact name of registrant as specified in its ...

PetMed Express, Inc. (NASDAQ:PETS) Q2 2021 Earnings Conference Call October 25, 2021 4:30 PM ET Company Representatives Matt Hulett - Chief Executive Officer Bruce Rosenbloom - Chief Financial Officer Conference Call Participants Anthony Lebiedzinski - Sidoti Steph Wissink - Jefferies Ben Rose - Battle Road Research Operator Welcome to the PetMeds Conference Call to Review the Financial Results for the Second Fiscal Quarter ended on September 30, 2021. At the request of the company, this conference call is ...